SCHEMBL25401220

SCHEMBL25401220

CC(=O)c1ccn2c(C(=O)c3ccccc3)cc(Br)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 8/20 0.51
▸ FNTB P49356 8/20 0.51
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ BAZ2B Q9UIF8 4/20 0.40
▸ BAZ2A Q9UIF9 4/20 0.40
▸ GLA P06280 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ BRD2 P25440 1/20 0.37
▸ BRD3 Q15059 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25400578 0.85 BAZ2B (0.45) ALDH1A1BAZ2BBAZ2ABRD4BRD2
SCHEMBL25402588 0.84 LMNA (0.46) FNTAFNTBALDH1A1HPGDHTT
SCHEMBL26301036 0.83 FNTA (0.51) FNTAFNTBALDH1A1HPGDSMN1; SMN2
SCHEMBL29547188 0.83 ALDH1A1 (0.40) FNTAFNTBALDH1A1NPSR1MAPT
SCHEMBL25400534 0.81 MAPT (0.43) FNTAFNTBALDH1A1HPGDSMN1; SMN2
SCHEMBL26301013 0.81 FNTA (0.49) FNTAFNTBALDH1A1HPGDSMN1; SMN2
SCHEMBL25402450 0.81 FNTA (0.68) FNTAFNTBALDH1A1HTTL3MBTL1
SCHEMBL25400667 0.78 FNTA (0.47) FNTAFNTBHPGDGLALMNA
SCHEMBL26301735 0.78 BAZ2B (0.46) FNTAFNTBALDH1A1HPGDSMN1; SMN2
SCHEMBL26301683 0.78 FNTA (0.46) FNTAFNTBALDH1A1HTTBAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4233864-B1 COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS UNIV AJOU IND ACADEMIC COOP FOUND (KR) 2025-02-12 — — EP disclosed
US-20230390319-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-12-07 — — US disclosed
EP-4233864-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT Ajou University Industry-Academic Cooperation Foundation (KR) 2023-08-30 — — EP disclosed
EP-4233864-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT Ajou University Industry-Academic Cooperation Foundation (KR) 2023-08-30 — — EP disclosed
WO-2022086260-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT 아주대학교산학협력단 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390319-A1 INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT STING1, IRF3, IFNG FNTA 2708/4885FNTB 2743/4885ALDH1A1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback